Magnetic resonance imaging (MRI) of inflamed myocardium using iron oxide nanoparticles in patients with acute myocardial infarction - Preliminary results

ObjectivesSuperparamagnetic iron oxide nanoparticle (SPIO)-based molecular imaging agents targeting macrophages have been developed and successfully applied in animal models of myocardial infarction. The purpose of this clinical trial was to investigate whether magnetic resonance imaging (MRI) of macrophages using ferucarbotran (Resovist®) allows improved visualisation of the myocardial (peri-)infarct zone compared to conventional gadolinium-based necrosis/fibrosis imaging in patients with acute myocardial infarction.Material and methodsThe clinical study NIMINI-1 was performed as a prospective, non-randomised, non-blinded, single agent phase III clinical trial (NCT0088644). Twenty patients who had experienced either an acute ST-elevation or non-ST-elevation myocardial infarction (STEMI/NSTEMI) were included to this study. Following coronary angiography, a first baseline cardiovascular magnetic resonance (CMR) study (pre-SPIO) was performed within seven days after onset of cardiac symptoms. A second CMR study (post-SPIO) was performed either 10 min, 4 h, 24 h or 48 h after ferucarbotran administration. The CMR studies comprised cine-CMR, T2-weighted “edema” imaging, T2*-weighted cardiac imaging and T1-weighted late-gadolinium-enhancement (LGE) imaging.ResultsThe median extent of short-axis in-plane LGE was 28% (IQR 19-31%). Following Resovist® administration the median extent of short-axis in-plane T2*-weighted hypoenhancement (suggestive of intramyocardial haemorrhage and/or SPIO accumulation) was 0% (IQR 0-9%; p = 0.68 compared to pre-SPIO). A significant in-slice increase (> 3%) in the extent of T2*-weighted “hypoenhancement” (post-SPIO compared to pre-SPIO) was seen in 6/16 patients (38%). However, no patient demonstrated “hypoenhancement” in T2*-weighted images following Resovist® administration that exceeded the area of LGE.ConclusionsT2/T2*-weighted MRI aiming at non-invasive myocardial macrophage imaging using the approved dose of ferucarbotran does not allow improved visualisation of the myocardial (peri-) infarct zone compared to conventional gadolinium-based necrosis/fibrosis imaging.